Shearman & Sterling represented BofA Securities, Morgan Stanley, Credit Suisse Securities (USA) and Deutsche Bank Securities as joint book-running managers and representatives of the underwriters in connection with Amgen’s registered $3 billion notes offering, consisting of $1,250,000,000 4.050% Senior Notes due 2029, $750,000,000 4.200% Senior Notes due 2033 and $1,000,000,000 4.875% Senior Notes due 2053. Amgen is a global biotechnology company that discovers, develops, manufactures and delivers human therapeutics based on advances in cellular and molecular biology.

The Team